Summary
AbbVie Inc. (ABBV) filed an 8-K on September 18, 2018, detailing a significant capital markets transaction. The company successfully issued and sold $6.0 billion in aggregate principal amount of senior notes across four different maturities: 2021, 2023, 2028, and 2048. These notes carry coupon rates ranging from 3.375% to 4.875%. This debt issuance was conducted through a registered public offering under a shelf registration statement and was pursuant to an underwriting agreement with several major financial institutions. The proceeds from this substantial debt offering are earmarked for strategic financial actions. AbbVie intends to use the funds, along with existing cash, to redeem or repay its outstanding $1.0 billion of 2.000% Senior Notes due 2018 and to prepay or repay its $2.0 billion Three-Year Term Loan Agreement. Any remaining proceeds will be allocated for general corporate purposes. This move signals proactive management of AbbVie's debt profile and capital structure.
Key Highlights
- 1AbbVie issued $6.0 billion in senior notes across four tranches: $1.25 billion (3.375% due 2021), $1.25 billion (3.750% due 2023), $1.75 billion (4.250% due 2028), and $1.75 billion (4.875% due 2048).
- 2The notes are unsecured, unsubordinated debt obligations of AbbVie, ranking equally with existing and future unsecured, unsubordinated indebtedness.
- 3Proceeds will be used to redeem $1.0 billion of 2.000% Senior Notes due 2018 and to repay $2.0 billion under its Three-Year Term Loan Agreement.
- 4The remaining proceeds from the offering are designated for general corporate purposes.
- 5The company entered into an underwriting agreement with major financial institutions including Merrill Lynch, J.P. Morgan, Morgan Stanley, and BNP Paribas.
- 6In conjunction with the note offering, AbbVie terminated its $2.0 billion unsecured Three-Year Term Loan Agreement.
- 7The filing incorporates information from a prospectus supplement dated September 13, 2018, and an indenture dated November 8, 2012, as supplemented.